Imipenem and Cilastatin Injection — FDA Drug Shortage

To Be Discontinued — Merck Sharp & Dohme Corp.

The FDA lists a drug shortage record for Imipenem and Cilastatin Injection (injection) from Merck Sharp & Dohme Corp. with status To Be Discontinued. The shortage was first posted on Jan 8, 2026.

Shortage details

Status
To Be Discontinued
Company
Merck Sharp & Dohme Corp.
Package NDC
0006-3516-59
Dosage Form
Injection
Presentation
Primaxin, Injection, 500mg (NDC 0006-3516-59)
Initial Posting
Jan 8, 2026

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.